Decentralized Science as a Solution for Rejuvenation and Longevity
There is something deeply disturbing in the discovery that there is a ceiling for human longevity. 120 to 150 years. No matter how many diseases we cure, how many tumors we eradicate, how many arteries we unclog. According to the studies published by Gero in Nature Communications in 2021 and 2022, the human body, as a complex system operating near a critical instability point, simply loses its fundamental capacity to return to equilibrium. Resilience — the property that allows an organism to absorb perturbations and recover its homeostasis — is not eternal, as demonstrated by the longitudinal analysis of millions of blood test measurements and physical activity patterns. It dissipates, exponentially, like a clock that decelerates until it stops. What Pyrkov and Fedichev discovered when analyzing individual aging trajectories is that the organism’s recovery time increases from approximately two weeks at age 40 to more than eight weeks at age 90, and the mathematical extrapolation of this trend points to a complete divergence (zero resilience) precisely in the range of 120 to 150 years.
When I first encountered Gero’s articles, I immediately recognized something that transcended traditional molecular biology. It wasn’t just another paper about telomeres or cellular senescence. It was a paradigmatic revolution: aging described not as a catalog of accumulated diseases, but as a predictable dynamic trajectory of a system on the brink of collapse.
And the most impressive part?
Pfizer decided to bet on this approach. This tells me something crucial: the industry finally understood that treating diseases individually is like mopping ice. You can eliminate cancer, defeat Alzheimer’s, cure diabetes. And still, as the researchers themselves conclude in their work, the entire system will continue its inexorable march toward disintegration. Because the problem is not in the parts; it’s in the emergent instability of the whole. And when a corporation that moves billions validates a theory based on complex systems physics and machine learning, it’s not about academic charity, but rather the recognition that the paradigm has shifted.
But here’s the point I seek to address. If the 120-150 year limit identified by Pyrkov and collaborators’ theoretical model is a fundamental barrier determined by the physics of dynamic instability — and the data from multiple independent systems (blood markers and physical activity) converging on the same critical point strongly suggest that it is —, then the only rational strategy is not to make use of “pharmaceutical incrementalism.”
The authors themselves indicate that effective therapies would need to reduce the parameter α (the system’s instability rate) or increase the energy barrier that separates healthy states from fragile states. We’re talking about modifying this fundamental parameter that governs the rate at which the body loses its self-regulation capacity. We’re talking about resetting epigenetic clocks in hematopoietic stem cells, as suggested by the strong correlation observed between the hematopoietic system and systemic aging. We’re talking, essentially, about rejuvenation. And here lies my central thesis: decentralized science is the only viable path to achieve this goal in useful time.
A large pharmaceutical company can invest in discovering targets for fibrotic diseases using Gero’s platform, because fibrosis has a clear market, as evidenced by the Pfizer-Gero collaboration itself announced in 2023. But betting on systemic epigenetic reprogramming? On therapies that potentially extend healthspan in ways that don’t generate continuous dependence on medications? That challenges the business model. Decentralized science is not tied to these constraints. It can explore territories that venture capital considers too speculative. It can fail loudly, iterate rapidly, and share discoveries in real time without waiting for patents or regulatory approvals. It can, fundamentally, operate at the speed that the urgency of the problem demands.
But there’s something even more fundamental here worth saying: decentralized science radically democratizes who can contribute to this revolution. DeSci is the viable path to rejuvenation because it enables researchers from the most remote areas of the world to formulate hypotheses and conduct their investigations freely, without the institutional and geographical barriers that have historically concentrated scientific progress in a few centers of excellence. A researcher in Manaus, another in Lagos, a third in some small town in the interior of Pakistan — all can access papers, implement the neural network architectures described, collect longitudinal data on blood markers and physical activity in their communities, and test hypotheses about interventions that modify the parameter α. The internet and the open-source movement transformed knowledge that was once locked in elite university libraries into something universally accessible.
Consider the DOSI — the Dynamic Organism State Indicator developed by Gero’s team. This is not just another biomarker. According to the technical description published in Nature Communications, it is an order parameter in the most rigorous physical sense of the term, a variable that captures the macroscopic state of a complex system near a phase transition. DOSI doesn’t measure how much you’ve deviated from youth; it measures the dynamics — how quickly you recover equilibrium after perturbations. Technically, it is the best numerical fit for the order parameter associated with the disintegration of the organism’s state, extracted through an artificial neural network that combines a deep autoencoder with an autoregressive model. What makes this revolutionary is not just the theoretical elegance, but its implementability. The authors published the complete methodology. Anyone with knowledge in machine learning and access to longitudinal blood test data can, in principle, reproduce the model. Rapamycin, for example, showed detectable deceleration of dFI (DOSI’s variant for mice) in just eight weeks of treatment. This means that a modest laboratory anywhere in the world can, with basic blood collection equipment and computational capacity that can be rented for pennies in the cloud, begin testing interventions and measuring results in weeks. We don’t need to wait for 30-year mortality studies conducted exclusively by elite institutions. We can measure, iterate, share, reproduce globally. The barrier between hypothesis and validation collapses, and geography ceases to be a determining factor.
The Langevin equation that governs DOSI’s evolution (dz/dt = αz + gz² + f(t), where z is the DOSI, α is the instability rate, g is the non-linear term and f(t) represents stochastic forces) does not have explicit time in its coefficients. As the authors themselves emphasize, chronological age is merely a proxy for how much the system has diverged from its initial state of stability. This has a profound implication that the researchers mention but don’t fully explore: the phenomenon is not fundamentally determined by “how many years you have,” but by “how unstable your system has become.” And instability, in principle, can be reversed. We’re not fighting against time as an abstract concept, but against a dynamic bifurcation that can, potentially, be restored to its stable regime through appropriate interventions that modify α or the structure of the energy potential that governs the system’s stability. And this mathematical formulation, published openly, can be studied, criticized, refined and tested by anyone who masters physics or applied mathematics, regardless of being affiliated with a university, regardless of whether they possess a credential or not.
This is where the urgency becomes visceral. If we accept that 120-150 years is the absolute limit identified by the independent convergence of multiple biological systems in Gero’s analysis (and the cross-validation between blood markers and physical activity patterns make this difficult to ignore), then we have a finite window. For those of us alive today, the clock is ticking not only in our own bodies, but in the scientific race to develop effective interventions before our generation crosses the threshold of irreversibility. The theoretical model suggests that there is a point of no return when DOSI reaches critical values, and the observation that animals scheduled for euthanasia due to excessive morbidity already present DOSI at the saturation levels observed in population data reinforces this interpretation.
I’m not proposing scientific anarchy or abandonment of methodological rigor. I’m proposing coordinated acceleration through distributed networks that maintain standards of evidence but operate outside the traditional structures that, by institutional design, prioritize safety over innovation. As demonstrated by Pyrkov and collaborators’ analysis, if the zero-resilience limit is somewhere between 120 and 150 years, and if the loss of resilience measured by the increase in autocorrelation time accelerates exponentially with a doubling rate compatible with the Gompertz Law of mortality, then for most people alive today, the horizon of opportunity for effective interventions may be only a few decades.
This is my hypothesis. And time doesn’t wait for us to decide if we’re ready for this revolution. But perhaps, just perhaps, the solution won’t come from where everyone expects. Perhaps it will come from a brilliant researcher in some unlikely place in the world who, having free access to knowledge but without the institutional constraints of major centers, will formulate the right hypothesis and test it with the speed that only truly decentralized science allows.
Feel free to contact me via email for any needs: contact@antoniovfranco.com